In the current study, we report that early elevation of serum YKL-40 reduces the risk of having NAFLD, the hepatic expression of metabolic syndrome, as assessed by the L/S ratio. This evidence concerns the gene CHI3L1 and metabolic dysfunction-associated steatotic liver disease.